Pilot and Feasibility - Alpha-1 Foundation
Forecasted
Pilot and Feasibility from the Alpha-1 Foundation supports researchers testing new hypotheses or methods relevant to alpha-1 antitrypsin deficiency to improve health and work toward a cure.
Browse similar grants
Funder: Alpha-1 Foundation
Due Dates (Anticipated): February 2027 (Full application) | September 2027 (LOI)
Funding Amounts: Up to $75,000 for one year
Summary: Supports development and testing of new hypotheses or methods relevant to alpha-1 antitrypsin deficiency.
Key Information: Pharmaceutical companies, biotechs, and industry cannot apply or collaborate on proposals.
Description
The Alpha-1 Foundation’s Pilot and Feasibility grant supports the development and testing of new hypotheses or new methods relevant to alpha-1 antitrypsin deficiency (AATD). Part of the Foundation’s In-Cycle Grants Award Program, it funds meritorious research designed to improve the health of people with AAT deficiency, with the ultimate goal of finding a cure.
The Foundation’s broader research mission encompasses Alpha-1-related lung and liver disease, as well as ethical, legal, and social issues affecting people with genetic conditions. Within that broader mission, Pilot and Feasibility specifically emphasizes exploring new research ideas and approaches connected to AATD.
